Humanization of an anti-p185HER2 antibody for human cancer therapy - sprookjes - yvandenbroek - TriplyDB

Humanization of an anti-p185HER2 antibody for human cancer therapy

Humanization of an anti-p185HER2 antibody for human cancer therapy

http://www.wikidata.org/entity/Q24561842

about

A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4 Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells Cholesterol loading and ultrastable protein interactions determine the level of tumor marker required for optimal isolation of cancer cells Critical appraisal of trastuzumab in treatment of advanced stomach cancer Human immunoglobulin allotypes: possible implications for immunogenicity ErbB receptors: from oncogenes to targeted cancer therapies Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer The antitumor immune response in HER-2 positive, metastatic breast cancer patients.Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy Targeting insulin and insulin-like growth factor signaling in breast cancer Fluorescent imaging of cancerous tissues for targeted surgery.Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges Newer therapies for the treatment of metastatic breast cancer: a clinical update Mnk kinase pathway: Cellular functions and biological outcomes Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer Integrins Influence the Size and Dynamics of Signaling Microclusters in a Pyk2-dependent Manner Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer The structure of an entire noncovalent immunoglobulin kappa light-chain dimer (Bence-Jones protein) reveals a weak and unusual constant domains association Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains Structural and Functional Analysis of a C3b-specific Antibody That Selectively Inhibits the Alternative Pathway of Complement Hedgehog Pathway Antagonist 5E1 Binds Hedgehog at the Pseudo-active Site Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein General strategy for the generation of human antibody variable domains with increased aggregation resistance Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors Patient-derived tumour xenografts for breast cancer drug discovery ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers From bench to bedside: lessons learned in translating preclinical studies in cancer drug development Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody Outcome of a workshop on applications of protein models in biomedical research

P2860

Q22010068-5FBEF9BA-4FC5-469F-88AF-7F99A2630DF9 Q24309891-D388FCF9-6FE2-40CA-928F-02A7E99634F1 Q24336447-270A97F4-79ED-40C6-A328-2936093A3F3E Q24561962-E045D883-19D4-4DB7-B589-EE362FB574CD Q24594878-4FA2065D-3F9E-494E-9A5B-95CAA7F349CE Q24604411-F180C413-D8E5-4EC6-8A07-C76CB31DCDD2 Q24651893-FAC2E38B-7378-4DB6-9C0A-29D89E3E53DB Q24683709-5377C224-0AD6-4951-AF74-E509D44E81A4 Q24795614-2A1DAC3C-8045-4F13-B01B-A347C5DBFD0F Q24796706-75F23B5E-B762-4253-A467-C3AE7CAD554F Q24815250-2DF96199-F1DC-4C34-AAC0-E713D11EBB16 Q26766713-A5B60B37-A121-423C-9BED-8C693612D40F Q26824462-11C53E8E-5ABD-4AFA-88F5-9042E0F1A003 Q26826380-CEAC7E15-AE34-4980-BC7F-B5B465D0422F Q26830905-BE855992-A00A-40EE-9871-F849B6BC1F7E Q26864808-5FCD6AE6-3C4F-4682-AC48-4B9E6A509AE0 Q26865260-9C9773AD-F0AA-4136-80E3-F765B81718AE Q26865459-64832AA2-A838-4155-A118-A1C1AB673DC2 Q27003258-B235E958-57B7-4623-AEED-8E977D02A1C6 Q27314180-29B8302B-A97A-4F92-941E-34F9FF5EF494 Q27314840-4D7229D6-B93D-4CA5-9DEE-694A74C0AD00 Q27617742-F23939E0-17EE-4680-A324-440857701EE2 Q27649162-3EB0D835-1262-4171-862B-65017A28B2F8 Q27653668-DE2FF069-A785-4482-9ABD-A99D16D4F323 Q27661941-C1FB20F8-207F-4584-92AB-DFA30469A073 Q27667382-C24F36B8-6D46-4AB7-B3A3-B219BD6C5565 Q27670560-1E7E1426-FDBA-4A9C-BAC4-B368274E68F9 Q27678647-083EF791-2104-4891-B5F2-C1D566B75A54 Q27679191-685D4A0B-69FF-4143-9F8D-86269749A229 Q27683825-E2E56B56-B62B-4073-8581-180B9F9708CE Q27851975-49C4A560-7CE1-4B28-891F-4B4D33A15970 Q28080046-16ED3E1D-AE31-4B1C-B1AC-6480441F5785 Q28084565-29A02827-11B7-4D8E-90D3-F0D07FE4ED8B Q28140238-0981C7C7-F816-499B-A863-5FC08E77494F Q28375856-C9846120-F2D5-498D-A494-3CFF5B251D0E Q28533949-20F4FDF9-15AD-4E1C-B635-D4F35C6E2753 Q28542825-19006519-3B75-44D0-B12C-BD88FCB3E087 Q28546010-AB394AC1-33FF-45E6-94FE-9CAD4C8AB249 Q28731515-9C506F31-272C-4E5F-A9D6-5AF815D0984B Q28751701-B460979C-28D5-4992-8B19-8C16F5EE6E4E

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

http://www.wikidata.org/entity/Q24561842

description

1992 nî lūn-bûn

@nan

1992 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1992年の論文

@ja

1992年学术文章

@wuu

1992年学术文章

@zh-cn

1992年学术文章

@zh-hans

1992年学术文章

@zh-my

1992年学术文章

@zh-sg

1992年學術文章

@yue

name

Humanization of an anti-p185HER2 antibody for human cancer therapy

@ast

Humanization of an anti-p185HER2 antibody for human cancer therapy

@en

Humanization of an anti-p185HER2 antibody for human cancer therapy

@nl

type

label

Humanization of an anti-p185HER2 antibody for human cancer therapy

@ast

Humanization of an anti-p185HER2 antibody for human cancer therapy

@en

Humanization of an anti-p185HER2 antibody for human cancer therapy

@nl

prefLabel

Humanization of an anti-p185HER2 antibody for human cancer therapy

@ast

Humanization of an anti-p185HER2 antibody for human cancer therapy

@en

Humanization of an anti-p185HER2 antibody for human cancer therapy

@nl

P1433

Q24561842-19B5FE65-18CA-4816-925A-0A0DCB7A1271

P1476

Q24561842-6B9DAA39-6F84-46D3-8676-91B8C86A07E6

P2093

Q24561842-04FB6E6F-8E5E-4555-80C8-646B11B2CDA5

Q24561842-1542892D-F014-4C36-B555-05063EF61236

Q24561842-1E75F274-CAFC-4174-B403-675CB8C8E30C

Q24561842-6CC9FBB7-84CC-4D1B-B47B-DB108A135301

Q24561842-707EF736-6DBF-4BE3-B178-55FE12A4C542

Q24561842-8DF1FBD2-BEEC-4FEB-969D-F1AC3301D99A

Q24561842-93721E5C-6589-44A1-9F3A-D1A0C6B1A985

Q24561842-AA006502-08F7-49DB-B09F-250B37FF8671

Q24561842-D8EC31F2-CDCB-4BAD-8654-3B7B3736A112

Q24561842-EAA74E95-633E-440D-9219-31B12B528BDF

P2860

Q24561842-007CC7A8-A895-41B5-B58F-656481273C6C

Q24561842-0117B90E-00C6-44F7-B3B8-29DA514CF271

Q24561842-0BB6549D-D779-488A-87DF-389A220F2978

Q24561842-262B7313-6D5A-4E6D-A40C-0D7FE1CBD097

Q24561842-2A3DE89A-C01A-4A81-9822-A12310E80D32

Q24561842-2C507B44-AB2C-4EBA-B21C-4FC5F81596BF

Q24561842-3B69EDAC-8476-4DBA-B517-D48F9175346B

Q24561842-3B766A45-909E-449E-B671-3DC7EA2B4500

Q24561842-440FB2B6-B88A-41C2-BA11-B5EC821BF26A

Q24561842-4C78EACF-A834-47F1-9A15-821E641B6CDF

P304

Q24561842-BACA73C1-2A6D-49B0-8DDE-C662EC4F6ACC

P31

Q24561842-F1E26DAF-AAB3-45CB-B241-1498BA8C146A

P3181

Q24561842-274B685C-AD4F-4E45-8C4F-F79EDEF6CA5B

P356

Q24561842-C29DC53C-D07A-496D-AFD1-000B5DA936DF

P407

Q24561842-AD3168FD-8E17-40A0-98C6-53B2ED32B51C

P433

Q24561842-DA98415A-2941-4B4A-950D-674DACACC522

P478

Q24561842-4445E6DA-D29A-4547-8397-F5A6786BB514

P577

Q24561842-252E9F05-29ED-40F4-8593-FA0975879BBA

P5875

Q24561842-37C68B7D-D882-4420-AB68-51E49DBAAC38

P698

Q24561842-859DC4E1-9B8D-4867-9D1F-2C1D0A1AD731

P921

Q24561842-DB343DFC-2F4B-4844-934E-412F985B030E

P932

Q24561842-28ED1361-7321-4B99-8DDE-8CC13D08EC3E

P3181

P356

PNAS.89.10.4285

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Humanization of an anti-p185HER2 antibody for human cancer therapy

@en

P2093

A M Rowland

http://www.w3.org/2001/XMLSchema#string

C Kotts

http://www.w3.org/2001/XMLSchema#string

C M Gorman

http://www.w3.org/2001/XMLSchema#string

D Henner

http://www.w3.org/2001/XMLSchema#string

H M Shepard

http://www.w3.org/2001/XMLSchema#string

J B Ridgway

http://www.w3.org/2001/XMLSchema#string

L Presta

http://www.w3.org/2001/XMLSchema#string

M E Carver

http://www.w3.org/2001/XMLSchema#string

P Carter

http://www.w3.org/2001/XMLSchema#string

W L Wong

http://www.w3.org/2001/XMLSchema#string

P2860

DNA sequencing with chain-terminating inhibitors

The nucleotide sequence of a human immunoglobulin C gamma1 gene

A humanized antibody that binds to the interleukin 2 receptor

Rapid and efficient site-specific mutagenesis without phenotypic selection

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

The Protein Data Bank: a computer-based archival file for macromolecular structures

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product

Conformations of immunoglobulin hypervariable regions

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

Reshaping human antibodies for therapy

P304

4285-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

333890

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.89.10.4285

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

1992-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21805798

http://www.w3.org/2001/XMLSchema#string

P698

1350088

http://www.w3.org/2001/XMLSchema#string

P921

P932

49066

http://www.w3.org/2001/XMLSchema#string